Tools for Practice Outils pour la pratique


#359 Topical corticosteroids for atopic dermatitis – More than skin deep


CLINICAL QUESTION
QUESTION CLINIQUE
What are the benefits/harms of topical corticosteroids for atopic dermatitis in adults/children?


BOTTOM LINE
RÉSULTAT FINAL
Evidence is somewhat limited but topical corticosteroids are effective for atopic dermatitis and efficacy likely increases with potency. Once daily seems similarly effective to twice daily. If frequent flares, ‘weekend therapy’ (treatment 2-days/week to areas with recurrent flares) will help ~60% avoid a flare versus ~30% using placebo-cream over 16-weeks. Topical corticosteroids are well-tolerated for ≤6 weeks. Long-term harms are not available.



CFPCLearn Logo

Reading Tools for Practice Article can earn you MainPro+ Credits

La lecture d'articles d'outils de pratique peut vous permettre de gagner des crédits MainPro+

Join Now S’inscrire maintenant

Already a CFPCLearn Member? Log in

Déjà abonné à CMFCApprendre? Ouvrir une session



EVIDENCE
DONNÉES PROBANTES
  • Four systematic reviews of randomized controlled trials (RCTs) in past 10 years.1-4 Results statistically significant unless indicated.
  • Versus vehicle/moisturizer:
    • More children responded to topical corticosteroids, all-types combined: 65% versus 32% (vehicle/moisturizer), not compared statistically.1
    • 2-days/week (‘weekend therapy’) fluticasone 0.005-0.05% versus vehicle, for prevention.2
      • Patients with ≥1 flare over 16-20 weeks (4 RCTs, 718 patients): 28% versus 61% (vehicle), Number needed to treat (NNT)=3.
      • Others found similar.3
  • Lower versus higher potency:
    • Using 4-potency classification (examples): Mild (hydrocortisone 1%), moderate (hydrocortisone valerate 0.2%), high (betamethasone valerate 0.1%), very high (clobetasol dipropionate 0.05%).3
      • Mild versus more potent steroids, marked improvement at 1-5 weeks:3
        • 34% (mild) versus 52% (moderate) (4 RCTs, 449 patients), NNT=6.
        • 40% (mild) versus 71% (high) (9 RCTs, 458 patients), NNT=4.
      • Moderate or high potency steroids versus more potent. Results mixed:
        • Marked improvement 1-5 weeks, between-participant trials: No difference.3
        • Within same-participant trials: Appears higher potency better, statistics not interpretable.
    • Using 7-potency US classification: Gradual increase in efficacy but comparisons indirect (network meta-analysis), statistics not provided.4
  • Once versus twice daily, using same steroid: No difference (5 RCTs, 903 patients).3
  • Adverse events, limited information. Short-term (2-6 weeks):
    • Eczematous skin, skin thinning in <1% of patients on placebo/steroid (18 RCTs, 1533 patients). RCTs too short, inconsistent/poor reporting, difficult to measure adverse effects on diseased/thickened skin.3
    • Normal skin, mean epidermal thickness loss: 0% mild versus 26% very-potent steroids (24 RCTs, 309 patients without eczema).5

CONTEXT
CONTEXTE
  • Potency classifications inconsistent.6
  • Tacrolimus 0.1% is at least equivalent to moderate-potency topical corticosteroids.7
  • Guidelines: Optimal treatment regimens unclear, stepwise increased potency reasonable.8 Moisturizers strongly recommended for all patients.8


shamsuddin chaudhry March 4, 2024

Excellent topic for treatment of atopic dermatitis

shamsuddin chaudhry March 4, 2024

very helpfull topic


Latest Tools for Practice
Derniers outils pour la pratique

#363 Making a difference in indifference? Medications for apathy in dementia

In patients with dementia, how safe and effective are stimulants, antidepressants, and antipsychotics for treating apathy?
Read Lire 0.25 credits available Crédits disponibles

#362 Facing the Evidence in Acne, Part I: Oral contraceptives and spironolactone in females

How effective are combined oral contraceptives (COC) and spironolactone for treating acne of at least mild-moderate severity in females?
Read Lire 0.25 credits available Crédits disponibles

#361 Preventing RSV Infections in Infants

How safe and effective are monoclonal antibodies to prevent respiratory syncytial virus (RSV) infections in infants?
Read Lire 0.25 credits available Crédits disponibles

This content is certified for MainPro+ Credits, log in to access

Ce contenu est certifié pour les crédits MainPro+, Ouvrir une session


Author(s)
Auteur(s)
  • Émélie Braschi MD PhD CCFP
  • Jennifer Young MD CCFP-EM
  • G. Michael Allan MD CCFP

1. Fishbein AB, Mueller K, Lor J et al. J Pediatr Nurs. 2019 Jul-Aug; 47:36-43.

2. Van Zuuren EJ, Fedorowicz Z, Christensen R et al. Cochrane Database Syst Rev. 2017 Feb 6; 2(2):CD012119.

3. Lax SJ, Harvey J, Axon E et al. Cochrane Database Syst Rev. 2022 Mar 11; 3(3):CD013356.

4. Chu DK, Chu AWL, Rayner DG et al. J Allergy Clin Immunol. 2023; 152(6): 1493-1519.

5. Barnes L, Kaya Gurkan, Rollason V. Drug Saf. 2015 May; 38(5):493-509.

6. Bowie AC, Tadrous M, Egeberg et al. JAMA Dermatol. 2022 Jul 1; 158(7):796-800.

7. Braschi E, Moe S. Fancy Creams for Scaly Skin: Topical calcineurin inhibitors for atopic dermatitis Tools for Practice #345. Available at: https://cfpclearn.ca/tfp345/. Accessed on: January 2, 2024.

8. Sidbury R, Alikhan A, Bercovitch L, et al. J Am Acad Dermatol. 2023; 89(1):e1-e20.

Authors have no conflicts of interest to declare.